Graft-versus-host disease

JLM Ferrara, JE Levine, P Reddy, E Holler - The Lancet, 2009 - thelancet.com
Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

[HTML][HTML] Phagocytosis of apoptotic cells in homeostasis

S Arandjelovic, KS Ravichandran - Nature immunology, 2015 - nature.com
Human bodies collectively turn over about 200 billion to 300 billion cells every day. Such
turnover is an integral part of embryonic and postnatal development, as well as routine …

Advances in graft-versus-host disease biology and therapy

BR Blazar, WJ Murphy, M Abedi - Nature reviews immunology, 2012 - nature.com
Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …

Pathophysiology of GvHD and other HSCT-related major complications

S Ghimire, D Weber, E Mavin, XN Wang… - Frontiers in …, 2017 - frontiersin.org
For over 60 years, hematopoietic stem cell transplantation has been the major curative
therapy for several hematological and genetic disorders, but its efficacy is limited by the …

Guidelines on the use of extracorporeal photopheresis

R Knobler, G Berlin, P Calzavara‐Pinton… - Journal of the …, 2014 - Wiley Online Library
Background After the first investigational study on the use of extracorporeal photopheresis
for the treatment of cutaneous T‐cell lymphoma was published in 1983 with its subsequent …

[HTML][HTML] Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease

D Wolff, M Schleuning, S von Harsdorf, U Bacher… - Biology of Blood and …, 2011 - Elsevier
Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant
morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials …

European dermatology forum–updated guidelines on the use of extracorporeal photopheresis 2020–part 1

R Knobler, P Arenberger, A Arun… - Journal of the …, 2020 - Wiley Online Library
Background Following the first investigational study on the use of extracorporeal
photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this …

Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape

HT Greinix, F Ayuk, R Zeiser - Leukemia, 2022 - nature.com
Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor
prognosis and for decades no approved drug has been available to treat this serious …

Extracorporeal photopheresis—an overview

A Cho, C Jantschitsch, R Knobler - Frontiers in medicine, 2018 - frontiersin.org
Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Pathogenesis and management of graft-versus-host disease

SW Choi, JE Levine… - … and Allergy Clinics, 2010 - immunology.theclinics.com
Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for
various malignant and nonmalignant conditions. 1 The indication for its use has expanded …